Zhou Zhou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Zhou Zhou has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
Jing Kang
Department of Otolaryngology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences) Southern Medical University Guangdong China
2 shared publications- Pingjiang Ge
Department of Otolaryngology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences) Southern Medical University Guangzhou China
2 shared publications - Austin J. Scholp
Roy J. Carver Department of Biomedical Engineering University of Iowa Iowa City Iowa USA
1 shared publication - Chaoyang Ke
Department of Otorhinolaryngology-Head and Neck Surgery, Shenzhen People's Hospital, 2nd Clinical Medical College of Jinan University, 1st Affiliated Hospital of Southern University of Science and Technology, Shenzhen, Guangdong, China
1 shared publication - Fanqian Zeng
Department of Otorhinolaryngology-Head and Neck Surgery, Shenzhen People's Hospital, 2nd Clinical Medical College of Jinan University, 1st Affiliated Hospital of Southern University of Science and Technology, Shenzhen, Guangdong, China
1 shared publication - Jack Jiaqi Jiang
Department of Otolaryngology-Head and Neck Surgery, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin
1 shared publication
Latest Publications
- Open Access
- 2 November 2026
- Published by Wiley in World Journal of Otorhinolaryngology - Head and Neck Surgery
Botox Injection Combined With Partial Arytenoidectomy: A Novel Approach for Treatment of Episodic Laryngeal Breathing Disorders
Objective: The aim of this study was to develop effective treatments for episodic laryngeal breathing disorders (ELBD), a series of diverse obstructive respiratory disorders with an unknown pathogenesis. The diseases include paradoxical vocal fold motion/movement disorder (PVFMD), vocal cord dysfunction (VCD), irritable larynx syndrome (ILS), exercise‐induced laryngeal obstruction, and laryngospasm. Methods: Five patients with ELBD were involved in this study (60–81 years, average of 70 years), including three men and two women, who visited the otolaryngology outpatient department suffering from dyspnea several times. Bilateral vocal fold paralysis and asthma were excluded. An injection of initial botulinum toxin into the vocal cords was treated for each patient. If recurrence were to take place within 3 months after injection, a vocal cord process resection would be performed. The visual scale of perception was used for assessing preoperative and postoperative dyspnea. Results: All patients experienced symptoms of recurring dyspnea for a duration of 1–120 months. The average follow‐up duration was 14 months (6–24 months) after treatment. Dyspnea was relieved in two patients after the Botox injection alone. Three patients found relief after unilateral vocal cord process resection. All patients showed a significant reduction in postoperative dyspnea scale in VAS score. Conclusion: This study preliminarily explores the efficacy of combined Botox injection and partial arytenoidectomy as a therapeutic option for ELBD.
- 2 November 2026
- Published by Wiley in World Journal of Otorhinolaryngology - Head and Neck Surgery
Open AccessBotox Injection Combined With Partial Arytenoidectomy: A Novel Approach for Treatment of Episodic Laryngeal Breathing Disorders
Objective: The aim of this study was to develop effective treatments for episodic laryngeal breathing disorders (ELBD), a series of diverse obstructive respiratory disorders with an unknown pathogenesis. The diseases include paradoxical vocal fold motion/movement disorder (PVFMD), vocal cord dysfunction (VCD), irritable larynx syndrome (ILS), exercise‐induced laryngeal obstruction, and laryngospasm. Methods: Five patients with ELBD were involved in this study (60–81 years, average of 70 years), including three men and two women, who visited the otolaryngology outpatient department suffering from dyspnea several times. Bilateral vocal fold paralysis and asthma were excluded. An injection of initial botulinum toxin into the vocal cords was treated for each patient. If recurrence were to take place within 3 months after injection, a vocal cord process resection would be performed. The visual scale of perception was used for assessing preoperative and postoperative dyspnea. Results: All patients experienced symptoms of recurring dyspnea for a duration of 1–120 months. The average follow‐up duration was 14 months (6–24 months) after treatment. Dyspnea was relieved in two patients after the Botox injection alone. Three patients found relief after unilateral vocal cord process resection. All patients showed a significant reduction in postoperative dyspnea scale in VAS score. Conclusion: This study preliminarily explores the efficacy of combined Botox injection and partial arytenoidectomy as a therapeutic option for ELBD.
- 20 January 2023
- Published by Wiley in Clinical Otolaryngology
- Vol. 48 (3) , 436-441
Automated detection of glottic laryngeal carcinoma in laryngoscopic images from a multicentre database using a convolutional neural network
Objective: Little is known about the efficacy of using artificial intelligence (AI) to identify laryngeal carcinoma from images of vocal lesions taken in different hospitals with multiple laryngoscope systems. This multicentre study aimed to establish an AI system and provide a reliable auxiliary tool to screen for laryngeal carcinoma.Study design: Multicentre case–control study.Setting: Six tertiary care centres.Participants: Laryngoscopy images were collected from 2179 patients with vocal fold lesions.Outcome measures: An automatic detection system of laryngeal carcinoma was established and used to distinguish malignant and benign vocal lesions in 2179 laryngoscopy images acquired from 6 hospitals with 5 types of laryngoscopy systems. Pathological examination was the gold standard for identifying malignant and benign vocal lesions.Results: Out of 89 cases in the malignant group, the classifier was able to correctly identify laryngeal carcinoma in 66 patients (74.16%, sensitivity). Out of 640 cases in the benign group, the classifier was able to accurately assess the laryngeal lesion in 503 cases (78.59%, specificity). Furthermore, the region‐based convolutional neural network (R‐CNN) classifier achieved an overall accuracy of 78.05%, with a 95.63% negative predictive value and a 32.51% positive predictive value for the testing data set.Conclusion: This automatic diagnostic system has the potential to assist clinical laryngeal carcinoma diagnosis which may improve and standardise the diagnostic capacity of laryngologists using different laryngoscopes.
- 20 January 2023
- Published by Wiley in Clinical Otolaryngology
- Vol. 48 (3) , 436-441
Automated detection of glottic laryngeal carcinoma in laryngoscopic images from a multicentre database using a convolutional neural network
Objective: Little is known about the efficacy of using artificial intelligence (AI) to identify laryngeal carcinoma from images of vocal lesions taken in different hospitals with multiple laryngoscope systems. This multicentre study aimed to establish an AI system and provide a reliable auxiliary tool to screen for laryngeal carcinoma.Study design: Multicentre case–control study.Setting: Six tertiary care centres.Participants: Laryngoscopy images were collected from 2179 patients with vocal fold lesions.Outcome measures: An automatic detection system of laryngeal carcinoma was established and used to distinguish malignant and benign vocal lesions in 2179 laryngoscopy images acquired from 6 hospitals with 5 types of laryngoscopy systems. Pathological examination was the gold standard for identifying malignant and benign vocal lesions.Results: Out of 89 cases in the malignant group, the classifier was able to correctly identify laryngeal carcinoma in 66 patients (74.16%, sensitivity). Out of 640 cases in the benign group, the classifier was able to accurately assess the laryngeal lesion in 503 cases (78.59%, specificity). Furthermore, the region‐based convolutional neural network (R‐CNN) classifier achieved an overall accuracy of 78.05%, with a 95.63% negative predictive value and a 32.51% positive predictive value for the testing data set.Conclusion: This automatic diagnostic system has the potential to assist clinical laryngeal carcinoma diagnosis which may improve and standardise the diagnostic capacity of laryngologists using different laryngoscopes.
- Open Access
- 19 February 2020
- Published by SAGE Publications in Ear, Nose & Throat Journal
- Vol. 100 (3_suppl) , 309S-316S
Comparison of 2 Different Intratympanic Methylprednisolone Injection Schedules in Combination With Intravenous Dexamethasone for Unilateral Sudden Sensorineural Hearing Loss
Sudden sensorineural hearing loss is a common otologic disease in clinic. Systemic and intratympanic steroid treatment have been proved to be effective, but the regimens vary from center to center. The purpose of the study is to analyze the effects of the combined application of intravenous dexamethasone and intratympanic methylprednisolone injection in different time strategies for the treatment of unilateral sudden sensorineural hearing loss. A retrospective chart review was performed for the period from March 2016 to June 2018 at our Department of Otorhinolaryngology—Head and Neck Surgery. A total number of 61 patients who met the academy criteria for unilateral sudden hearing loss were included and grouped based on the time to introduce intratympanic methylprednisolone. All the patients received intravenous dexamethasone 10 mg once daily for 5 days, followed 5 mg once daily for the next 7 days. Intratympanic methylprednisolone (40 mg) was injected every other day 4 times into all patients. This regimen was commenced on day 1 in group 1 and on day 6 in group 2. The pre and posttreatment pure-tone audiograms were analyzed. Sixty-one patients met our inclusion criteria. No significant differences were observed between patients’ demographics or pretreatment hearing thresholds. In the 3 months posttreatment pure-tone audiogram assessment, the mean hearing threshold improvement were similar between groups with no frequency specificity. The curative rate in both groups were similar and satisfying. Two patients with diabetes mellitus had persistent small perforations. Some patients had other transient discomfort that disappeared before discharge. The different timing of initiation of intratympanic methylprednisolone injection does not significantly affect the outcome of the treatment for sudden sensorineural hearing loss. Thus, we suggest that intratympanic steroid injection should not be applied as a first-line method except for patients who do not respond early to systemic steroid therapy.
- 19 February 2020
- Published by SAGE Publications in Ear, Nose & Throat Journal
- Vol. 100 (3_suppl) , 309S-316S
Open AccessComparison of 2 Different Intratympanic Methylprednisolone Injection Schedules in Combination With Intravenous Dexamethasone for Unilateral Sudden Sensorineural Hearing Loss
Sudden sensorineural hearing loss is a common otologic disease in clinic. Systemic and intratympanic steroid treatment have been proved to be effective, but the regimens vary from center to center. The purpose of the study is to analyze the effects of the combined application of intravenous dexamethasone and intratympanic methylprednisolone injection in different time strategies for the treatment of unilateral sudden sensorineural hearing loss. A retrospective chart review was performed for the period from March 2016 to June 2018 at our Department of Otorhinolaryngology—Head and Neck Surgery. A total number of 61 patients who met the academy criteria for unilateral sudden hearing loss were included and grouped based on the time to introduce intratympanic methylprednisolone. All the patients received intravenous dexamethasone 10 mg once daily for 5 days, followed 5 mg once daily for the next 7 days. Intratympanic methylprednisolone (40 mg) was injected every other day 4 times into all patients. This regimen was commenced on day 1 in group 1 and on day 6 in group 2. The pre and posttreatment pure-tone audiograms were analyzed. Sixty-one patients met our inclusion criteria. No significant differences were observed between patients’ demographics or pretreatment hearing thresholds. In the 3 months posttreatment pure-tone audiogram assessment, the mean hearing threshold improvement were similar between groups with no frequency specificity. The curative rate in both groups were similar and satisfying. Two patients with diabetes mellitus had persistent small perforations. Some patients had other transient discomfort that disappeared before discharge. The different timing of initiation of intratympanic methylprednisolone injection does not significantly affect the outcome of the treatment for sudden sensorineural hearing loss. Thus, we suggest that intratympanic steroid injection should not be applied as a first-line method except for patients who do not respond early to systemic steroid therapy.